Salud financiera de hoja de balance de Innovent Biologics

Salud financiera controles de criterios 4/6

Innovent Biologics tiene un patrimonio de los accionistas total de CN¥12.5B y una deuda total de CN¥3.5B, lo que sitúa su ratio deuda-patrimonio en 28.1%. Sus activos y pasivos totales son CN¥20.6B y CN¥8.1B respectivamente.

Información clave

28.1%

Ratio deuda-patrimonio

CN¥3.52b

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	CN¥10.97b
Patrimonio	CN¥12.53b
Total pasivo	CN¥8.10b
Activos totales	CN¥20.63b

Actualizaciones recientes sobre salud financiera

No hay actualizaciones

Recent updates

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (CN¥13.4B) de IVBX.F superan a sus pasivos a corto plazo (CN¥4.5B).

Pasivo a largo plazo: Los activos a corto plazo de IVBX.F (CN¥13.4B) superan a sus pasivos a largo plazo (CN¥3.6B).

Historial y análisis de deuda-patrimonio

Nivel de deuda: IVBX.F tiene más efectivo que su deuda total.

Reducción de la deuda: El ratio deuda-patrimonio de IVBX.F ha crecido de 18.9% a 28.1% en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: IVBX.F tiene suficiente cash runway para más de 3 años basándose en su flujo de caja libre actual.

Pronóstico de cash runway: Datos insuficientes para determinar si IVBX.F tiene suficiente cash runway en caso de que su flujo de caja libre siga creciendo o disminuyendo basado en tasas históricas.

Salud financiera de hoja de balance de Innovent Biologics

Salud financiera controles de criterios 4/6

Información clave

Actualizaciones recientes sobre salud financiera

Recent updates

Innovent Biologics, Inc. Presents the Results of the First Phase 3 Study of Mazdutide for Weight Management at the ADA's 84th Scientific Sessions

Innovent Biologics, Inc. Announces Picankibart (IBI112) Achieved Primary Endpoints in A Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to the NDA to the NMPA

Innovent Biologics Announces National Medical Products Administration of China Accepts the New Drug Application for IBI311

Innovent Receives NMPA Breakthrough Therapy Designation for IBI343(Anti-Claudin18.2 ADC) as Monotherapy for Advanced Gastric Cancer

Innovent Biologics, Inc. Appoints Samuel Zhang as Global Chief Business Officer

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status

Innovent Biologics, Inc. Announces the National Medical Products Administration Accepts the New Drug Application

Innovent Biologics, Inc., Annual General Meeting, Jun 21, 2024

Innovent Biologics, Inc. Releases the Results of Two Clinical Studies of Ibi311 (An Anti-IGF-1R Monoclonal Antibody) in Oral Presentations At the Asia-Pacific Academy of Ophthalmology Congress and International Congress of Endocrinology 2024

Anheart Therapeutics and Innovent Announces China’s NMPA Accepted Second New Drug Application for Taletrectinib for First-Line Treatment of Ros1-Positive Lung Cancer

Innovent Biologics, Inc. to Report Fiscal Year 2023 Results on Mar 20, 2024

Innovent Biologics, Inc. Announces the Phase 3 Clinical Study of Ibi311 Met the Primary Endpoint in Treating Thyroid Eye Disease

Innovent Biologics, Inc. Announces Appointment of Shun Lu as Independent Non-Executive Director and A Member of the Strategy Committee

Innovent Biologics, Inc.'s First New Drug Application of Mazdutide for Chronic Weight Management Has Been Accepted by the NMPA of China

Innovent Biologics, Inc. Announces Chief Financial Officer Changes

Innovent Biologics, Inc. Announces the First Phase 3 Clinical Trial of Mazdutide Inchinese Adults with Overweight or Obesity Metthe Primary and All Key Secondary Endpoints

China’S National Medical Products Administration Grants Anheart Therapeutics and Innovent Biologics, Inc. Taletrectinib (Ros1 Inhibitor) Priority Review Designation for the New Drug Application (Nda) of Taletrectinib

Innovent Biologics, Inc. Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Overweight or Obesity in Nature Communications

Innovent Biologics, Inc. Announces the Phase 3 Orient-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

Innovent Biologics, Inc. Announces the National Medical Products Administration of China Accepts and Grants Priority Review Designation to the New Drug Application for IBI351

Innovent Biologics, Inc. Announces Acceptance of New Drug Application from National Medical Products Administration for Taletrectinib

Innovent Biologics, Inc Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Type 2 Diabetes in Diabetes Care

The National Medical Products Administration Approves Olverembatinib for the Treatment of Cml-Cp Patients

Innovent Biologics, Inc. Announces Robust Weight Loss Efficacy, Multiple Metabolic Benefits and Favorable Safety Profile of Higher Dose 9 mg Mazdutide (IBI362) after 48-week Treatment in Phase 2 Study for Obesity

Innovent Biologics, Inc. Announces Update on the New Drug Application for Parsaclisib (PI3Kd Inhibitor)

Innovent Biologics, Inc. has completed a Follow-on Equity Offering in the amount of HKD 2.35688 billion.

National Medical Products Administration Approves New Drug Application for Innovent Biologics, Inc.'s Sintbilo

Innovent Biologics, Inc. to Report Q2, 2023 Results on Aug 23, 2023

IASO Bio and Innovent Announce the NMPA Approval of the New Drug Application for Equecabtagene Autoleucel, the World's First Fully-human BCMA CAR-T Therapy, for the Treatment of Relapsed and/or Refractory Multiple Myeloma

Innovent Biologics, Inc. Announces Phase 1 Clinical Data of IBI322 (CD47/PD-L1 Bispecific Antibody) in the Treatment of Anti-PD-(L)1-Resistant Classic Hodgkin Lymphoma Patients at the EHA 2023 Annual Meeting

Innovent Presents Phase 1 Clinical Data of IBI351 as Monotherapy for Metastatic Colorectal Cancer at the 2023 ASCO Annual Meeting

Innovent Updates Phase 1B Data of IbI939 (Anti-Tigit Monoclonal Antibody) Combined with Sintilimab in Previously Untreated PD-L1-Selected NSCLC

Innovent Announces the Second Breakthrough Therapy Designation by NMPA for Olverembatinib for the Treatment of Patients with SDH-Deficient GIST

Innovent Biologics, Inc. Announces Phase 2 Clinical Study of Higher dose 9 mg Mazdutide (IBI362) in Chinese Adults with Obesity Achieved the 24-Week Primary Endpoint

Innovent Biologics, Inc. Announces National Medical Products Administration Approves TYVYT (Sintilimab Injection) in Combination with Bevacizumab and Chemotherapy in Patients with EGFR-Mutated Non-Squamous Nsclc Who Progressed After EGFR-TKI Therapy

Innovent Announces First Patient Dosed in a Phase 3 Clinical Trial (CLEAR) of Picankibart (Anti-IL23p19 Monoclonal Antibody) in Patients with Moderate-to-Severe Plaque Psoriasis

Innovent Biologics, Inc. Announces First Participant Dosed in Phase 2 Study of IBI311 (Anti-IGF-1R Monoclonal Antibody) in Patients with Thyroid Associated Ophthalmopathy

Innovent Announces Inclusion in the China National Reimbursement Drug List (NRDL) of TYVYT in Two New Indications, Olverembatinib for the First Listing, BYVASDA, HALPRYZA and SULINNO in Multiple New Indications

Innovent Biologics, Inc. Announces First Participant Dosed in A Phase 3 Clinical Study (Dreams-1) of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes

Innovent Biologics, Inc. Announces the National Medical Products Administration in China Has Accepted and Granted Priority Review Designation to the New Drug Application for Parsaclisib

Innovent Biologics, Inc. Presents Phase Ib Clinical Data Update of IBI110 (Anti-LAG-3 Monoclonal Antibody) at the 2022 European Society For Medical Oncology Immuno-Oncology Congress

Innovent and UNION Therapeutics Announce First Subject Dosed in a Chinese Clinical Phase I Study of the Novel PDE4 Inhibitor Orismilast (IBI353)

Innovent Announces First Participant Dosed in a Phase 3 Clinical Study (GLORY-1) of Mazdutide (IBI362) in Chinese Adults with Overweight or Obesity

Innovent Biologics, Inc. Releases Results of a Phase 3 Clinical Study of Tafolecimab(IBI306)in Chinese Patients with non- Familial Hypercholesterolemia at the American Heart Association (AHA) Scirntific Sessions 2022

Innovent Announces First Patient Dosing in Australia in Phase I Study of IBI343 (Recombinant anti-Claudin18.2 Monoclonal Antibody-drug Conjugate) in Patients with Advanced Solid Tumors

Innovent Announces Phase Ib Results of Higher-Dose Mazdutide (IBI362) in Chinese Participants with Overweight or Obesity Published in eClinicalmedicine

Innovent Announces Phase Ib Results of Higher-Dose Mazdutide (IBI362) in Chinese Participants with Overweight or Obesity Published in eClinicalmedicine

Innovent Biologics, Inc. Announces China NMPA Approves CYRAMZA (ramucirumab) for Treatment in Patients with Hepatocellular Carcinoma

Innovent Biologics, Inc. Announces Second Interim Analysis Results of the Randomized, Double-Blinded, Multi-Center Phase 3 ORIENT-31 Study

Innovent Biologics, Inc. Announces First Participant Dosed in the Higher-Dose Cohort of A Phase 2 Clinical Trial of Mazdutide in Chinese Adults with Obesity

Innovent Biologics, Inc. Announces First Participant Dosed in the Higher-Dose Cohort of A Phase 2 Clinical Trial of Mazdutide in Chinese Adults with Obesity

Innovent Biologics, Inc. Announces First Patient Dosing in Australia in Phase 1 Study of IBI363 (PD-1/IL-2 Bispecific Antibody Fusion Protein) in Patients with Advanced Malignancies

Innovent Biologics, Inc. Announces First Subject Dosed in Phase 1 Study of IBI311 (Anti-IGF-1R Monoclonal Antibody)

Innovent Announces Phase 2 Clinical Study of Picankibart (IBI112) in Chinese Patients with Moderate-to-Severe Plaque Psoriasis Met Primary Endpoint

Innovent Biologics, Inc. Announces First Patient Dosed in Phase 1 Study of IBI324 (VEGF-A/Ang-2 Bispecific Antibody) in Patients with Diabetic Macular Edema

Innovent Biologics, Inc. announced that it expects to receive HKD 4.83336 billion in funding from Sanofi Foreign Participations B.V.

Innovent Biologics, Inc. and Laekna Jointly Announce First Patient Dosed with Three-Drug Combination in a Phase 1/2 Study for the Treatment of Patients with Solid Tumors Who Were Resistant to Prior Anti-PD-1/PD-L1 Therapy

Innovent Biologics, Inc. Announces CDE Accepts and Grants Priority Review Designation to New Drug Application

Innovent Announces Phase 2 Study of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes Met Primary Endpoint

Innovent Biologics, Inc. Announces First Patient Dosed in a Phase 2 Clinical Study of IBI112 (IL-23p19 Monoclonal Antibody) in Patients with Moderate-to-Severe Active Ulcerative Colitis

Innovent Announces Phase 1b Study Results of Mazdutide (IBI362) in Chinese Patients with Type 2 Diabetes Published in Nature Communications

Innovent Biologics, Inc. and Eli Lilly and Company Jointly Announces Approval of TYVYT by China NMPA in Combination with Chemotherapy as First-Line Treatment of Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

The National Medical Products Administration Approves the Supplemental New Drug Application for TYVYT® (Sintilimab Injection) in Combination with Chemotherapy as First-Line Treatment for Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Innovent and Lilly Jointly Announce the Approval of TYVYT (sintilimab injection) by China NMPA in Combination with Chemotherapy as First-Line Treatment for Esophageal Squamous Cell Carcinoma

Innovent Announces the NMPA Acceptance of the New Drug Application for Tafolecimab Injection (anti-PCSK-9 antibody)

Innovent Biologics, Inc. and IASO Biotherapeutics Presents Updated Data of BCMA CAR-T Cell Therapy (Equecabtagene Autoleucel) at EHA 2022

Innovent Biologics, Inc. Announces Phase 2 Study of Mazdutide(Ibi362 in Chinese Participants with Overweight or Obesity Met Primary and All Key Secondary Endpoints

AnHeart Therapeutics and Innovent Biologics Present Updated Phase 2 Efficacy and Safety Data of Taletrectinib (ROS1 Inhibitor) at ASCO 2022

Innovent Biologics, Inc. Presents Clinical Data of Phase I Study for IBI351 (KRAS G12C Inhibitor)

IASO Bio and Innovent Jointly Announce the NMPA Acceptance of the New Drug Application for Equecabtagene Autoleucel for the Treatment of Relapsed and/or Refractory Multiple Myeloma

Innovent Appoints Gary Zieziula as Independent Non-Executive Director

Innovent to Present Clinical Data of IBI110 (anti-LAG-3 monoclonal antibody) and Other Multiple Trials at the 2022 American Society of Clinical Oncology Annual Meeting

Innovent Biologics, Inc. Receives NMPA Breakthrough Designation for IBI310, the Anti-CTLA-4 Monoclonal Antibody, Combined with Sintilimab in Advanced Cervical Cancer Treatment

Innovent Biologics, Inc. Releases Phase 1 Results of IBI322 (Anti-PD-L1/CD47 Bispecific Antibody) in Patients with Advanced Solid Tumors at AACR Annual Meeting 2022

Innovent Announces Approval of Pemazyre (pemigatinib) by National Medical Products Administration for the Treatment of Adults with Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Rearrangement